285 related articles for article (PubMed ID: 27602494)
1. Extracellular domain shedding influences specific tumor uptake and organ distribution of the EGFR PET tracer 89Zr-imgatuzumab.
Pool M; Kol A; Lub-de Hooge MN; Gerdes CA; de Jong S; de Vries EG; Terwisscha van Scheltinga AG
Oncotarget; 2016 Oct; 7(42):68111-68121. PubMed ID: 27602494
[TBL] [Abstract][Full Text] [Related]
2. Human Epidermal Growth Factor Receptor 3-Specific Tumor Uptake and Biodistribution of
Warnders FJ; Terwisscha van Scheltinga AGT; Knuehl C; van Roy M; de Vries EFJ; Kosterink JGW; de Vries EGE; Lub-de Hooge MN
J Nucl Med; 2017 Aug; 58(8):1210-1215. PubMed ID: 28360206
[TBL] [Abstract][Full Text] [Related]
3. Imaging the distribution of an antibody-drug conjugate constituent targeting mesothelin with ⁸⁹Zr and IRDye 800CW in mice bearing human pancreatic tumor xenografts.
ter Weele EJ; Terwisscha van Scheltinga AG; Kosterink JG; Pot L; Vedelaar SR; Lamberts LE; Williams SP; Lub-de Hooge MN; de Vries EG
Oncotarget; 2015 Dec; 6(39):42081-90. PubMed ID: 26536664
[TBL] [Abstract][Full Text] [Related]
4. In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft.
Nagengast WB; de Vries EG; Hospers GA; Mulder NH; de Jong JR; Hollema H; Brouwers AH; van Dongen GA; Perk LR; Lub-de Hooge MN
J Nucl Med; 2007 Aug; 48(8):1313-9. PubMed ID: 17631557
[TBL] [Abstract][Full Text] [Related]
5. Development and characterization of 89Zr-labeled panitumumab for immuno-positron emission tomographic imaging of the epidermal growth factor receptor.
Chang AJ; De Silva RA; Lapi SE
Mol Imaging; 2013; 12(1):17-27. PubMed ID: 23348788
[TBL] [Abstract][Full Text] [Related]
6. ImmunoPET and biodistribution with human epidermal growth factor receptor 3 targeting antibody ⁸⁹Zr-RG7116.
Terwisscha van Scheltinga AG; Lub-de Hooge MN; Abiraj K; Schröder CP; Pot L; Bossenmaier B; Thomas M; Hölzlwimmer G; Friess T; Kosterink JG; de Vries EG
MAbs; 2014; 6(4):1051-8. PubMed ID: 24870719
[TBL] [Abstract][Full Text] [Related]
7. Immuno-PET imaging for non-invasive assessment of cetuximab accumulation in non-small cell lung cancer.
Yamaguchi A; Achmad A; Hanaoka H; Heryanto YD; Bhattarai A; Ratianto ; Khongorzul E; Shintawati R; Kartamihardja AAP; Kanai A; Sugo Y; S Ishioka N; Higuchi T; Tsushima Y
BMC Cancer; 2019 Oct; 19(1):1000. PubMed ID: 31651282
[TBL] [Abstract][Full Text] [Related]
8. In vivo visualization of MET tumor expression and anticalin biodistribution with the MET-specific anticalin 89Zr-PRS-110 PET tracer.
Terwisscha van Scheltinga AG; Lub-de Hooge MN; Hinner MJ; Verheijen RB; Allersdorfer A; Hülsmeyer M; Nagengast WB; Schröder CP; Kosterink JG; de Vries EG; Audoly L; Olwill SA
J Nucl Med; 2014 Apr; 55(4):665-71. PubMed ID: 24614223
[TBL] [Abstract][Full Text] [Related]
9. CD38 as a PET Imaging Target in Lung Cancer.
Ehlerding EB; England CG; Jiang D; Graves SA; Kang L; Lacognata S; Barnhart TE; Cai W
Mol Pharm; 2017 Jul; 14(7):2400-2406. PubMed ID: 28573863
[TBL] [Abstract][Full Text] [Related]
10. Measurement of tumor VEGF-A levels with 89Zr-bevacizumab PET as an early biomarker for the antiangiogenic effect of everolimus treatment in an ovarian cancer xenograft model.
van der Bilt AR; Terwisscha van Scheltinga AG; Timmer-Bosscha H; Schröder CP; Pot L; Kosterink JG; van der Zee AG; Lub-de Hooge MN; de Jong S; de Vries EG; Reyners AK
Clin Cancer Res; 2012 Nov; 18(22):6306-14. PubMed ID: 23014526
[TBL] [Abstract][Full Text] [Related]
11. PET imaging of epidermal growth factor receptor expression in tumours using 89Zr-labelled ZEGFR:2377 affibody molecules.
Garousi J; Andersson KG; Mitran B; Pichl ML; Ståhl S; Orlova A; Löfblom J; Tolmachev V
Int J Oncol; 2016 Apr; 48(4):1325-32. PubMed ID: 26847636
[TBL] [Abstract][Full Text] [Related]
12. Non invasive imaging assessment of the biodistribution of GSK2849330, an ADCC and CDC optimized anti HER3 mAb, and its role in tumor macrophage recruitment in human tumor-bearing mice.
Alsaid H; Skedzielewski T; Rambo MV; Hunsinger K; Hoang B; Fieles W; Long ER; Tunstead J; Vugts DJ; Cleveland M; Clarke N; Matheny C; Jucker BM
PLoS One; 2017; 12(4):e0176075. PubMed ID: 28448604
[TBL] [Abstract][Full Text] [Related]
13. Positron emission tomography (PET) imaging with [11C]-labeled erlotinib: a micro-PET study on mice with lung tumor xenografts.
Memon AA; Jakobsen S; Dagnaes-Hansen F; Sorensen BS; Keiding S; Nexo E
Cancer Res; 2009 Feb; 69(3):873-8. PubMed ID: 19155297
[TBL] [Abstract][Full Text] [Related]
14. ImmunoPET Imaging of CTLA-4 Expression in Mouse Models of Non-small Cell Lung Cancer.
Ehlerding EB; England CG; Majewski RL; Valdovinos HF; Jiang D; Liu G; McNeel DG; Nickles RJ; Cai W
Mol Pharm; 2017 May; 14(5):1782-1789. PubMed ID: 28388076
[TBL] [Abstract][Full Text] [Related]
15. ADCC responses and blocking of EGFR-mediated signaling and cell growth by combining the anti-EGFR antibodies imgatuzumab and cetuximab in NSCLC cells.
Kol A; Terwisscha van Scheltinga A; Pool M; Gerdes C; de Vries E; de Jong S
Oncotarget; 2017 Jul; 8(28):45432-45446. PubMed ID: 28467975
[TBL] [Abstract][Full Text] [Related]
16. ImmunoPET Imaging of CD146 in Murine Models of Intrapulmonary Metastasis of Non-Small Cell Lung Cancer.
England CG; Jiang D; Hernandez R; Sun H; Valdovinos HF; Ehlerding EB; Engle JW; Yang Y; Huang P; Cai W
Mol Pharm; 2017 Oct; 14(10):3239-3247. PubMed ID: 28825843
[TBL] [Abstract][Full Text] [Related]
17. Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30.
Perk LR; Stigter-van Walsum M; Visser GW; Kloet RW; Vosjan MJ; Leemans CR; Giaccone G; Albano R; Comoglio PM; van Dongen GA
Eur J Nucl Med Mol Imaging; 2008 Oct; 35(10):1857-67. PubMed ID: 18491091
[TBL] [Abstract][Full Text] [Related]
18. Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET.
Aerts HJ; Dubois L; Perk L; Vermaelen P; van Dongen GA; Wouters BG; Lambin P
J Nucl Med; 2009 Jan; 50(1):123-31. PubMed ID: 19091906
[TBL] [Abstract][Full Text] [Related]
19. Receptor-binding, biodistribution, and metabolism studies of 64Cu-DOTA-cetuximab, a PET-imaging agent for epidermal growth-factor receptor-positive tumors.
Ping Li W; Meyer LA; Capretto DA; Sherman CD; Anderson CJ
Cancer Biother Radiopharm; 2008 Apr; 23(2):158-71. PubMed ID: 18454685
[TBL] [Abstract][Full Text] [Related]
20. Preclinical Pharmacokinetics and Biodistribution Studies of 89Zr-Labeled Pembrolizumab.
England CG; Ehlerding EB; Hernandez R; Rekoske BT; Graves SA; Sun H; Liu G; McNeel DG; Barnhart TE; Cai W
J Nucl Med; 2017 Jan; 58(1):162-168. PubMed ID: 27493273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]